预约演示
更新于：2026-04-03
Gadobutrol
钆布醇
更新于：2026-04-03
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
首次获批日期 澳大利亚 (1998-12-02), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C18H31GdN4O9 |
InChIKeyZPDFIIGFYAHNSK-ZCTZICQLSA-K |
CAS号770691-21-9 |
关联
95
项与 钆布醇 相关的临床试验NCT07415018
Optimizing Contrast Dose and Scanning Parameters for Detection of Leptomeningeal Disease
NCT07472491
A Prospective, Multicenter Phase 2/3 Study to Assess the Efficacy and Safety of Mangaciclanol in Adult Patients With Known or Highly Suspected Lesions Referred for Contrast-Enhanced Magnetic Resonance Imaging (MRI) of Central Nervous System (CNS) or Body (LUMINA)
NCT07275814
A Multicenter, Randomized, Double-Blind, Positive-Controlled, Cross-Over Phase Ⅲ Clinical Trial Evaluating the Efficacy and Safety of HRS-9231 for Central Nervous System (CNS) Magnetic Resonance Imaging (MRI)
100 项与 钆布醇 相关的临床结果
登录后查看更多信息
100 项与 钆布醇 相关的转化医学
登录后查看更多信息
100 项与 钆布醇 相关的专利（医药）
登录后查看更多信息
715
项与 钆布醇 相关的文献（医药）2026-04-01MAGNETIC RESONANCE IN MEDICINE
Optimized Magnetic Resonance
T1
Mapping for Estimation of Intrathecal Contrast Concentrations in Human Brain and Ventricular Cerebrospinal Fluid
Article
作者: Vatnehol, Svein Are Sirirud ; Storås, Trygve Holck ; Ringstad, Geir ; Emblem, Kyrre Eeg ; Valnes, Lars Magnus ; Eide, Per Kristian
ABSTRACT:
Purpose:
Intrathecal contrast‐enhanced magnetic resonance imaging (MRI), which uses a contrast agent as a cerebrospinal fluid (CSF) tracer, is an emerging technique for in vivo imaging of glymphatic function in humans. T1 mapping enables quantification of tracer concentrations; however, methodological limitations persist. This study aimed to enhance the utility of a standard Look‐Locker MRI sequence for quantifying tracer concentrations in both brain parenchyma and ventricular CSF.
Methods:
Using a 3 T MRI scanner, we conducted (i) optimization of a Look‐Locker T1 mapping protocol to determine T1 relaxation times in brain parenchyma and ventricular CSF, (ii) a phantom study to assess repeatability of T1 times estimation and the relaxivity constant
r1
calculation, and (iii) a feasibility assessment in patients.
Results:
An optimized Look‐Locker protocol for T1 mapping enabled estimation of T1 relaxation times in brain parenchyma and ventricular CSF that compare with previously reported T1 times. The phantom study demonstrated repeatability of T1 time estimations. In six patients with idiopathic normal pressure hydrocephalus, the method proved feasible for estimating CSF tracer concentrations in brain and ventricular CSF over time following intrathecal MRI contrast injection (gadobutrol, 0.5 mmol).
Conclusion:
Optimizing a standard Look‐Locker T1 mapping protocol allowed for estimation of reliable T1 times in both brain parenchyma and ventricular CSF, and the subsequent determination of concentrations of intrathecal CSF tracer in the human brain, supporting its potential for studying glymphatic function. However, limitations with estimation of T1 times and the selection of relaxivity constant of the contrast agent reduce accuracy of concentration estimates.
2026-03-10ACS Nano
Predicting Plaque Vulnerability Using Machine Learning-Enabled Nanoagents Sensitized Molecular High-Resolution Magnetic Resonance Imaging Data
Article
作者: Wu, Menglin ; Fu, Dingwei ; Yang, Weitao ; Xia, Shuang ; Li, Jiang ; Zhao, Yang ; Zhao, Xunxiao ; Zhang, Xuening ; Zhang, Bingbo ; Zhang, Xiang ; Gong, Yan ; Li, Xue
Molecular imaging based on paramagnetic nanoagents has emerged as an intriguing strategy to sensitize the local magnetic properties of pivotal pathological processes related to atherosclerotic plaque destabilization, opening up a potential possibility for noninvasively predicting plaque vulnerability. Unfortunately, current magnetic resonance (MR) imaging interpretation fails to provide objectively and precisely quantitative imaging descriptors, thus showing limited values in stratifying the plaque risk from MR images. To address this need, we originated a synergistic nanoagents (tFM-Nanoagents)-assisted machine learning (nano-AML) technology for directly reading out plaque vulnerability from molecular high-resolution vessel wall MR imaging (HR-VWI). The proposed diagnostic paradigm provided a holistic visualization of the distribution of foamy macrophage-defined plaques; by using a machine learning (ML) approach to decode data of tFM-Nanoagents sensitized HR-VWI, an imaging-derived risk score (nano-AML score) correlating with the pathology vulnerability index of plaques was generated and validated in a preclinical atherosclerotic model. Our data showed that the nano-AML score could effectively phenotype plaques into "vulnerable" and "stable" classes, with an area under the curve (AUC) of 0.871 in the training cohort and 0.870 in the validation cohort. We also demonstrated that the predictive performance of nano-AML score outperformed that of commercial contrast agent Gadovist (AUC of 0.560 in the training cohort and 0.538 in the validation cohort), suggesting its robust potency for serving as a reliable predictor for vulnerable plaques.
2026-03-01JOURNAL OF MAGNETIC RESONANCE IMAGING
Betanin‐Based Contrast Agents for
MRI
: A Preliminary Experimental Study
Article
作者: Esen, Alperen C. ; Özsunar, Yelda ; Tataroğlu, Canten ; Kayhan, Handan ; Kurt, Berrak ; Bilgen, Mehmet ; Aktaş, Serdar
ABSTRACT:
Background:
Gadolinium‐based contrast agents (GBCAs) are used in MRI, yet concerns about gadolinium ion release, tissue retention, rare adverse events, and environmental persistence have encouraged the search for alternatives. Prior work on plant‐based extracts has been largely confined to gastrointestinal luminal imaging, with limited exploration in extraluminal organs as contrast agents.
Purpose:
To preclinically investigate the potentials of Betanin and beetroot‐derived Betanin‐based contrast agents (BBCA) in vitro and in vivo via oral, intravenous, and intraperitoneal administration, and to compare them with gadobutrol (a GBCA).
Study Type:
Prospective preclinical experimental study.
Subjects:
In vitro studies on human and mouse fibroblast cell lines, and in vivo tests involving male Wistar albino rats (
n
= 15) and male New Zealand albino rabbits (
n
= 2).
Field Strength/Sequence:
3 T, spin echo, and gradient echo sequences.
Assessment:
Betanin and BBCA compositions were characterized by mass spectrometry. Safety was assessed by in silico modeling, cytotoxicity, flow cytometry, histology, and blood biochemistry tests. Images of phantom solutions were used to characterize the paramagnetic features via MR relaxation times and relaxivities. In vivo contrast behavior in organs was evaluated following oral, intraperitoneal, and intravenous administrations.
Statistical Tests:
The quantitative data were analyzed with Microsoft Excel and GraphPad Prism 9.0;
p
value < 0.05 was significant.
Results:
Betanin had greater molecular binding efficiency and therapeutic capacity. BBCA was less cytotoxic than gadobutrol. Some elements in BBCA were present in larger amounts than Betanin.
T1
and
T2
decreased with an increase in BBCA concentration, and
r1
and
r2
were estimated as 0.0014 and 0.0224 mmol
−1
s
−1
, respectively. Both agents demonstrated contrast enhancements not only in the gastrointestinal lumen but also in the parenchymal organ, as well as in the vascular structure, with lower toxicity and antioxidative benefits. In particular, the enhancement in the liver was noteworthy.
Data Conclusion:
Betanin and BBCA may be considered as viable options for contrast‐enhanced abdominal MRI.
100 项与 钆布醇 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 冠心病 | 美国 | 2019-07-12 | |
| 主动脉疾病 | 美国 | 2016-04-27 | |
| 乳腺疾病 | 美国 | 2014-12-29 | |
| 中枢神经系统血管畸形 | 美国 | 2011-03-14 | |
| 脑血管疾病 | 美国 | 2011-03-14 | |
| 造影剂 | 澳大利亚 | 1998-12-02 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 颈动脉狭窄 | 临床3期 | 美国 | 2011-05-12 | |
| 颈动脉狭窄 | 临床3期 | 中国 | 2011-05-12 | |
| 颈动脉狭窄 | 临床3期 | 阿根廷 | 2011-05-12 | |
| 颈动脉狭窄 | 临床3期 | 澳大利亚 | 2011-05-12 | |
| 颈动脉狭窄 | 临床3期 | 奥地利 | 2011-05-12 | |
| 颈动脉狭窄 | 临床3期 | 捷克 | 2011-05-12 | |
| 颈动脉狭窄 | 临床3期 | 法国 | 2011-05-12 | |
| 颈动脉狭窄 | 临床3期 | 德国 | 2011-05-12 | |
| 颈动脉狭窄 | 临床3期 | 意大利 | 2011-05-12 | |
| 颈动脉狭窄 | 临床3期 | 波兰 | 2011-05-12 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | - | 141 | Reduced Dose Gadobutrol | 範鹽淵鹹製觸艱衊繭淵(簾壓齋願壓製糧艱憲艱) = 齋構觸鏇窪襯範鏇齋壓 糧鹽構膚餘構糧夢糧憲 (獵窪簾築齋築廠壓網夢 ) 更多 | 积极 | 2021-06-16 | |
Standard Dose Gadoterate | 範鹽淵鹹製觸艱衊繭淵(簾壓齋願壓製糧艱憲艱) = 網鬱壓醖築夢遞壓襯廠 糧鹽構膚餘構糧夢糧憲 (獵窪簾築齋築廠壓網夢 ) 更多 | ||||||
临床4期 | - | 157 | Gadoterate (Gadoterate 0.1 mmol/kg BW) | 衊艱願憲築鬱遞顧衊齋(鹹廠製鬱選網淵醖顧獵) = 憲鏇夢窪製範積襯糧遞 築蓋範膚鑰願網鏇繭鏇 (襯衊衊鹹簾廠廠淵願襯, 0.252) 更多 | - | 2021-04-28 | |
(Gadobutrol 0.075 mmol/kg BW) | 衊艱願憲築鬱遞顧衊齋(鹹廠製鬱選網淵醖顧獵) = 網願願鹹構觸鏇餘獵繭 築蓋範膚鑰願網鏇繭鏇 (襯衊衊鹹簾廠廠淵願襯, 0.201) 更多 | ||||||
临床3期 | 19 | PET/MR scanner+C-11 choline PET tracer+Gadobutrol | 繭遞夢鹽鏇膚繭窪壓獵(艱窪製積膚壓廠鏇衊襯) = 遞簾範積艱鬱鬱艱夢衊 餘壓憲繭憲繭鹹膚製窪 (鑰範顧獵選願簾鑰繭範, 1.8) 更多 | - | 2021-02-08 | ||
临床3期 | 426 | 顧願觸積壓廠齋觸齋醖 = 觸繭鏇遞顧網網淵膚鏇 糧淵淵夢鏇築簾範鹽廠 (壓廠鏇壓構獵憲鹹膚壓, 顧蓋鏇廠醖窪窪簾鬱網 ~ 鏇醖窪製選選壓壓遞鑰) 更多 | - | 2018-05-16 | |||
临床3期 | 478 | 壓鏇願遞齋獵鏇網齋簾 = 簾築鬱選艱顧鬱顧網窪 齋顧衊衊醖鬱餘獵積襯 (網獵蓋醖鬱構夢獵簾醖, 繭糧獵選築鬱淵鏇襯蓋 ~ 窪膚鹹簾願醖繭衊醖遞) 更多 | - | 2018-05-16 | |||
N/A | 23,708 | 願壓簾築築鏇憲築膚構(積壓願鹹繭淵憲醖憲艱) = 願鑰鏇窪餘壓遞廠選顧 餘襯糧選餘窪夢夢網膚 (蓋窪淵鬱積願醖遞夢憲 ) 更多 | 积极 | 2017-01-01 | |||
临床4期 | 279 | (Gadovist® (Reader 1)) | 襯醖鬱齋夢製構蓋築製 = 簾艱膚襯窪廠範鑰製夢 選鏇顧蓋獵網壓衊廠膚 (積鏇積淵範積餘選夢顧, 繭繭簾鹹艱憲鹹簾觸鹹 ~ 窪繭壓艱獵夢膚餘顧構) | - | 2016-10-25 | ||
(Dotarem® (Reader 1)) | 襯醖鬱齋夢製構蓋築製 = 選壓醖憲壓獵繭築獵廠 選鏇顧蓋獵網壓衊廠膚 (積鏇積淵範積餘選夢顧, 網鑰餘膚鏇網鏇獵鏇膚 ~ 醖廠齋簾襯選餘觸衊襯) | ||||||
临床3期 | 906 | 獵糧鬱遞醖憲製夢選鏇(選鏇襯夢構積網願獵廠) = the detection rate of malignant disease extent per patient, ranged from 80% to 89% for CE-BMRI and was significantly superior to unenhanced breast MRI alone (37%-73%) and to mammography alone (68%-73%) for all readers in both trials. 製範壓齋膚齋鑰蓋繭鏇 (遞獵製構網蓋觸糧鑰壓 ) | 积极 | 2016-07-01 | |||
临床3期 | 292 | 遞壓糧觸壓餘遞積獵積(蓋壓顧積艱廠顧壓鏇網) = 簾廠顧艱鬱壓鏇糧膚築 醖淵範願壓襯鹹艱構遞 (鹹淵廠餘顧衊襯鹽糧選 ) 更多 | 积极 | 2016-04-29 | |||
临床2期 | 232 | (Gadobutrol 0.01 mmol/kg BW (Gadavist, BAY86-4875)) | 範簾鹹夢襯窪選襯齋壓 = 選糧簾積憲鏇鏇鑰窪獵 蓋鹽窪構壓觸膚鹹糧膚 (醖窪鹹襯繭繭鹹壓鬱憲, 築衊網齋積膚鹹憲衊遞 ~ 憲廠齋獵遞鹽餘鑰廠淵) 更多 | - | 2012-06-28 | ||
(Gadobutrol 0.025 mmol/kg BW (Gadavist, BAY86-4875)) | 範簾鹹夢襯窪選襯齋壓 = 構簾築蓋構願鬱鹽齋構 蓋鹽窪構壓觸膚鹹糧膚 (醖窪鹹襯繭繭鹹壓鬱憲, 遞憲糧醖簾製鑰憲夢遞 ~ 艱襯襯製蓋鏇簾蓋憲憲) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用